Navigation Links
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Date:4/9/2008

Phase 1 study marks the achievement of a critical milestone in our clinical development program and further supports our strategy of focusing on orally-administered, small molecule drugs with multiple mechanisms of action. Data from preclinical studies with ENMD-2076 demonstrate its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 study, we expect to not only determine ENMD-2076's safety profile and appropriate Phase 2 dosing schedule, but which tumor types may be better suited for this compound. We plan to initiate a second Phase 1 study in patients with hematological cancers later this year."

James S. Burns, EntreMed President & Chief Executive Officer commented, "ENMD-2076 is an exciting selective kinase inhibitor with potent single agent activity that has induced tumor regression in multiple preclinical models. ENMD-2076, developed internally, is consistent with our focus on investing behind oncology drug candidates with strong single-agent activity and with our continuing interest in selective kinase inhibitors. In parallel with the clinical trial, we will seek a pharmaceutical or biotech partner to help accelerate the development of our novel selective kinase inhibitor."

The administration of ENMD-2076 to the first patient in this important Phase 1 study will trigger a milestone payment by EntreMed pursuant to EntreMed's acquisition of Miikana Therapeutics, Inc. in January 2006. Under the terms of the merger agreement with Miikana, the dosing of the first patient triggers a $2 million payment to the former Miikana stockholders, either in cash or shares of EntreMed common stock.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. EN
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
2. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
3. EntreMed to Present at The New York Society of Security Analysts Industry Conference
4. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
5. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
6. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
7. EntreMed Raises $20 Million to Support Clinical Development Program
8. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... JERUSALEM , August 19, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Intellectual Property Department of ... patent for its invention, titled "Methods and Compositions ... Oramed Pharmaceuticals  Oramed Pharmaceuticals is a ...
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
(Date:8/19/2014)... ,Weight Loss- Market Analysis, Global API Manufacturers ... insights about phase III pipeline drugs and marketed drugs ... is to establish the understanding for API Manufacturers for ... countries and regions. While the leading brands, companies and ... on the drug master filings across the US, ...
Breaking Medicine Technology:Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, manufacturer ... announced financial results the third quarter ended September 30, 2009. , , ... ... Q3 2008 ...
... TRIANGLE PARK, N.C., Nov. 12 Chimerix, Inc., ... address life-threatening diseases, announced today that Kenneth I. ... overview at two upcoming investor conferences. Mr. ... pipeline, including CMX001, a broad-spectrum antiviral being developed ...
Cached Medicine Technology:Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results 11Chimerix to Present at Two Upcoming Investor Conferences 2
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... , TUESDAY, Oct. 11 (HealthDay News) -- A small, preliminary study ... intestines -- a potential sign that the pills might reduce the ... be done, and the researchers aren,t yet recommending that people head ... meal times. "If you want to add ginger to part ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay ... raises the risk for both breast and ovarian cancer are ... new study indicates. Those other women include both women ... of breast and ovarian cancer, and women without ...
... A team of scientists led by a Penn State ... an alternative method of molecular depth profiling -- a ... such as human tissue, nanoparticles, and other substances. In ... modeling to show the effectiveness and limitations of the ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
... intersection density and well-connected streets in towns and cities ... according to a Queen,s University study. "We,ve known ... a high density of intersections in a given areahelps ... and more efficient for them to walk to work ...
... TUESDAY, Oct. 11 (HealthDay News) -- Nearly 90 percent of ... well-being, according to a new national poll of 1,000 voters. ... also revealed that by having routine mammograms, women gain a ... that poll results show that nearly nine in 10 women ...
Cached Medicine News:Health News:Ginger Supplements Might Ease Inflammation Linked to Colon Cancer 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 2Health News:Molecular depth profiling modeled using buckyballs and low-energy argon 3Health News:New project examines medical safety net for undocumented patients 2Health News:Women Say Mammograms Give Them Sense of Control: Survey 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: